Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Eledon Pharmaceuticals, Inc. - Common Stock
(NQ:
ELDN
)
2.620
+0.200 (+8.26%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eledon Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results
August 14, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
August 07, 2025
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
August 07, 2025
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
August 06, 2025
Via
Benzinga
Stay updated with the stocks that are on the move in today's after-hours session.
↗
August 06, 2025
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.
Via
Chartmill
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
August 06, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025
July 30, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
↗
July 28, 2025
Via
Benzinga
Updated Data from Eledon Pharmaceuticals’ Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025
July 17, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City
June 25, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results
May 14, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results
March 20, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference
March 04, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human
February 07, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference
January 29, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook
January 13, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
November 12, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference
November 06, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
David-Alexandre (‘DA’) Gros, CEO of Eledon Pharmaceuticals Inc. (NASDAQ: ELDN), to Present at NobleCon20
November 06, 2024
Via
Investor Brand Network
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
October 30, 2024
Via
Benzinga
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
October 29, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
October 29, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
September 11, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients
September 04, 2024
Enrollment Completed Four Months Ahead of Schedule
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
ELDN Stock Earnings: Eledon Pharma Misses EPS for Q2 2024
↗
August 19, 2024
ELDN stock results show that Eledon Pharma missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results
August 14, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection
July 29, 2024
80 Participants (Two-thirds of Projected Recruitment) Enrolled
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
July 02, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Penny Stock Picks: 3 Companies Poised to Graduate to the Big Leagues
↗
June 17, 2024
You don’t want to overlook these three penny stocks filled to the brim with the potential to make huge leaps in their respective markets.
Via
InvestorPlace
3 High-Potential Penny Stocks to Turn $1000 into $1 Million: June 2024
↗
June 11, 2024
Although the very idea of millionaire-maker penny stocks implies incredibly high risks, if all cylinders fire, these companies could fly.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.